Literature DB >> 31993498

ADAMDEC1 and FGF2/FGFR1 signaling constitute a positive feedback loop to maintain GBM cancer stem cells.

Ana Jimenez-Pascual1, Justin D Lathia2,3, Florian A Siebzehnrubl1.   

Abstract

Identification of targetable mechanisms that maintain glioblastoma cancer stem cells (CSCs) remain a priority. Our study reveals a new mechanism by which a disintegrin and metalloproteinase domain-like protein decysin 1 promotes CSC maintenance through the activation of a fibroblast growth factor autocrine signaling loop, which can be blocked pharmacologically.
© 2019 Taylor & Francis Group, LLC.

Entities:  

Keywords:  FGF2; FGFR1; ZEB1; glioblastoma; patient-derived xenograft

Year:  2019        PMID： 31993498      PMCID： PMC6961677          DOI： 10.1080/23723556.2019.1684787

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  8 in total

1.  Oncogenes Activate an Autonomous Transcriptional Regulatory Circuit That Drives Glioblastoma.

Authors:  Dinesh K Singh; Rahul K Kollipara; Vamsidara Vemireddy; Xiao-Li Yang; Yuxiao Sun; Nanda Regmi; Stefan Klingler; Kimmo J Hatanpaa; Jack Raisanen; Steve K Cho; Shyam Sirasanagandla; Suraj Nannepaga; Sara Piccirillo; Tomoyuki Mashimo; Shan Wang; Caroline G Humphries; Bruce Mickey; Elizabeth A Maher; Hongwu Zheng; Ryung S Kim; Ralf Kittler; Robert M Bachoo
Journal:  Cell Rep       Date:  2017-01-24       Impact factor: 9.423

2.  The soluble protease ADAMDEC1 released from activated platelets hydrolyzes platelet membrane pro-epidermal growth factor (EGF) to active high-molecular-weight EGF.

Authors:  Rui Chen; Ge Jin; Thomas M McIntyre
Journal:  J Biol Chem       Date:  2017-04-28       Impact factor: 5.157

3.  Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens.

Authors:  Steven M Pollard; Koichi Yoshikawa; Ian D Clarke; Davide Danovi; Stefan Stricker; Roslin Russell; Jane Bayani; Renee Head; Marco Lee; Mark Bernstein; Jeremy A Squire; Austin Smith; Peter Dirks
Journal:  Cell Stem Cell       Date:  2009-06-05       Impact factor: 24.633

4.  Transforming fusions of FGFR and TACC genes in human glioblastoma.

Authors:  Devendra Singh; Joseph Minhow Chan; Pietro Zoppoli; Francesco Niola; Ryan Sullivan; Angelica Castano; Eric Minwei Liu; Jonathan Reichel; Paola Porrati; Serena Pellegatta; Kunlong Qiu; Zhibo Gao; Michele Ceccarelli; Riccardo Riccardi; Daniel J Brat; Abhijit Guha; Ken Aldape; John G Golfinos; David Zagzag; Tom Mikkelsen; Gaetano Finocchiaro; Anna Lasorella; Raul Rabadan; Antonio Iavarone
Journal:  Science       Date:  2012-07-26       Impact factor: 47.728

5.  αvβ3 Integrin and Fibroblast growth factor receptor 1 (FGFR1): Prognostic factors in a phase I-II clinical trial associating continuous administration of Tipifarnib with radiotherapy for patients with newly diagnosed glioblastoma.

Authors:  Anne Ducassou; Emmanuelle Uro-Coste; Pierre Verrelle; Thomas Filleron; Alexandra Benouaich-Amiel; Vincent Lubrano; Jean-Christophe Sol; Marie-Bernadette Delisle; Gilles Favre; Solea Ken; Anne Laprie; Peter De Porre; Christine Toulas; Muriel Poublanc; Elizabeth Cohen-Jonathan Moyal
Journal:  Eur J Cancer       Date:  2013-04-06       Impact factor: 9.162

6.  A laminin 511 matrix is regulated by TAZ and functions as the ligand for the α6Bβ1 integrin to sustain breast cancer stem cells.

Authors:  Cheng Chang; Hira Lal Goel; Huijie Gao; Bryan Pursell; Leonard D Shultz; Dale L Greiner; Sulev Ingerpuu; Manuel Patarroyo; Shiliang Cao; Elgene Lim; Junhao Mao; Karen Kulju McKee; Peter D Yurchenco; Arthur M Mercurio
Journal:  Genes Dev       Date:  2015-01-01       Impact factor: 11.361

7.  The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance.

Authors:  Florian A Siebzehnrubl; Daniel J Silver; Bugra Tugertimur; Loic P Deleyrolle; Dorit Siebzehnrubl; Matthew R Sarkisian; Kelly G Devers; Antony T Yachnis; Marius D Kupper; Daniel Neal; Nancy H Nabilsi; Michael P Kladde; Oleg Suslov; Simone Brabletz; Thomas Brabletz; Brent A Reynolds; Dennis A Steindler
Journal:  EMBO Mol Med       Date:  2013-07-01       Impact factor: 12.137

8.  FGFR1/FOXM1 pathway: a key regulator of glioblastoma stem cells radioresistance and a prognosis biomarker.

Authors:  Elizabeth Cohen-Jonathan Moyal; Christine Toulas; Valérie Gouazé-Andersson; Marie-Julie Ghérardi; Anthony Lemarié; Julia Gilhodes; Vincent Lubrano; Florent Arnauduc
Journal:  Oncotarget       Date:  2018-08-03
  8 in total
  2 in total

1.  Bioinformatic Analysis Reveals Central Role for Tumor-Infiltrating Immune Cells in Uveal Melanoma Progression.

Authors:  Mieszko Lachota; Anton Lennikov; Karl-Johan Malmberg; Radoslaw Zagozdzon
Journal:  J Immunol Res       Date:  2021-06-11       Impact factor: 4.818

Review 2.  Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma.

Authors:  Julie Bolcaen; Shankari Nair; Cathryn H S Driver; Tebatso M G Boshomane; Thomas Ebenhan; Charlot Vandevoorde
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.